SEC Form 4 · accession 0001230724-26-000010
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Guggenhime
Officer — PRESIDENT AND CFO
Period of report
Jun 18, 2026
Accepted (ET)
Jun 18, 2026 · 8:07 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 18, 2026 | M | 10,000 | $5.35 | A | 114,395 | D | |
| Common Stock | Jun 18, 2026 | S | 10,000 | $53.00 | D | 104,395 | D | |
| Common StockF2 | holding | — | — | — | 61,850 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $5.35 | Jun 18, 2026 | M | 10,000 | D | — | May 11, 2030 | Common Stock | 10,000 | 236,827 | D |
Explanation of responses
- F1The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.
- F2Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.
- F3Option is fully vested and exercisable.